Telix Pharmaceuticals (ASX:TLX) has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK).
Telix is developing 89Zr-girentuximab (TLX-250) for the purpose of imaging clear cell renal cell cancer (ccRCC) with Positron Emission Tomography (PET).
Under the collaboration, MSK will use TLX-250 as a tool to better manage the therapeutic algorithm for patients with metastatic ccRCC by using imaging to assess early treatment response to standard care drugs.
"The clinical objective is to use imaging as a precision medicine tool to rapidly determine an optimal therapeutic strategy for the patient," said Telix in a statement.
Telix co-founder and CEO, Dr Christian Behrenbruch, said, “We believe treatment-response imaging with TLX-250 can fundamentally change the way we cycle patients through tyrosine kinase inhibitors (TKI), mTOR inhibitors and VEGF-targeting drugs to more recently available options such as nivolumab. In doing so, it is hoped that we can do a better job of maximizing therapeutic response for patients with advanced disease.”
As part of the collaboration, Telix will fund MSK’s implementation of a new radiochemistry process and will amend the existing study protocol for repeat dosing of 124I-girentuximab to take advantage of the superior sensitivity and specificity of using 89Zr (zirconium) chemistry.